Composition and method for reducing thrombocytopenia
Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.
1. A method of reducing thrombocytopenia, comprising administering plinabulin or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the thrombocytopenia is induced by administration of gemcitabine or a chemotherapeutic composition comprising gemcitabine.
2. The method of claim 1 , wherein the subject has a grade 1 thrombocytopenia.
3. The method of claim 1 , wherein the subject has a grade 2 thrombocytopenia.
4. The method of claim 1 , wherein the subject has a grade 3 thrombocytopenia.
5. The method of claim 1 , wherein the subject has a grade 4 thrombocytopenia.
6. The method of claim 1 , wherein the plinabulin is administered at a dose in the range of about 2.5 mg/m 2 to about 17.5 mg/m 2 .
7. The method of claim 1 , wherein the plinabulin is administered at a dose in the range of about 8.5 mg/m 2 to about 32.5 mg/m 2 .
8. The method of claim 1 , wherein the plinabulin is administered at a dose in the range of about 9.5 mg/m 2 to about 15.5 mg/m 2 .
9. The method of claim 1 , wherein the plinabulin is administered at a dose in the range of about 15.5 mg/m 2 to about 24.5 mg/m 2 .
10. The method of claim 1 , further comprising administering gemcitabine prior to administering plinabulin.
11. The method of claim 10 , wherein the gemcitabine is administered about 1 hour prior to plinabulin administration.
12. The method of claim 1 , comprising reducing an incidence of a thrombocytopenia by at least 10%.
13. The method of claim 1 , comprising reducing an incidence of a thrombocytopenia by at least 30%.
14. The method of claim 1 , comprising reducing a duration of a thrombocytopenia by at least 50%.
15. A method of increasing platelet production, stimulating platelet formation, or increasing platelet count in a subject being administered gemcitabine, comprising administering plinabulin or a pharmaceutically acceptable salt thereof to the subject in need thereof.
16. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 1 mg/m 2 to about 50 mg/m 2 .
17. The method of claim 15 , wherein the subject has a grade 1 thrombocytopenia.
18. The method of claim 15 , wherein the subject has a grade 2 thrombocytopenia.
19. The method of claim 15 , wherein the subject has a grade 3 thrombocytopenia.
20. The method of claim 15 , wherein the subject has a grade 4 thrombocytopenia.
21. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 2.5 mg/m 2 to about 17.5 mg/m 2 .
22. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 8.5 mg/m 2 to about 32.5 mg/m 2 .
23. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 9.5 mg/m 2 to about 15.5 mg/m 2 .
24. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 15.5 mg/m 2 to about 24.5 mg/m 2 .
25. The method of claim 15 , wherein the plinabulin is administered at a dose in the range of about 22.5 mg/m 2 to about 32.5 mg/m 2 .
26. The method of claim 15 , further comprising administering gemcitabine prior to administering plinabulin.
27. The method of claim 26 , wherein the gemcitabine is administered about 1 hour prior to plinabulin administration.
28. The method of claim 15 , comprising reducing an incidence of a thrombocytopenia by at least 10%.
29. The method of claim 15 , comprising reducing an incidence of a thrombocytopenia by at least 30%.
30. The method of claim 15 , comprising reducing a duration of a thrombocytopenia by at least 50%.
31. A method of treating thrombocytopenia, comprising:
identifying a subject having a breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, or bladder cancer; and
administering plinabulin or a pharmaceutically acceptable salt thereof to the subject in need thereof at a dose in the range of about 1 mg/m 2 to about 50 mg/m 2 to the subject;
wherein the thrombocytopenia is induced by administration of gemcitabine or a chemotherapeutic composition comprising gemcitabine.